Skip to main content

Data Analytics

/assets/FullWidthImages/Data-Analytics-v2.png

Imaging biomarker data interrogated by the IXI™ Platform, together with IXICO’s expert scientists and world-renowned neuroradiologists, translates complex data into clinically meaningful information.

The Platform provides a secure and compliant environment for the collection, analysis and interpretation of large image files and other data that may be generated in the course of a clinical study.

Image analysis algorithms are disease contextualised and data-driven to analyse data from people with specific neurological diseases. Algorithms are also robust to inherent variability between patients, disease stages, scanners and image quality to provide accurate analysis results.

AI Biomarker Algorithms

Highly differentiated algorithms measuring existing and previously inaccessible biomarkers at scale, with high precision

  • AI-led accurate assessment of brain pathologies and disease-specific symptoms, identifying over 150 brain structures, quantifying the changes in both whole-brain and regional volumes over the time course of a clinical trial.
  • Validates measures of function and biochemical characteristics across the identified brain regions.
  • Provides trial sponsors with detailed insights into the pipeline drug’s effect on disease progression.
  • Regulatory compliant (GCP and 21 CFR Part 11).

Brain Region Analytics

Reading Platform

Performing brain region analysis on individual scans to measure brain volume both at a single time point and across multiple time points.

  • Supports critical patient-level decision-making, including providing insights into patient eligibility and drug efficacy.
  • ‘Global’ measurements on the whole brain and ‘regional’ measurements of specific local brain regions.
  • Human-expert-equivalent analysis at a faster pace and with higher levels of consistency and replicability.
  • The capability to be trained on a specific problem using data for a precise brain region in a particular therapeutic indication
  • Regulatory compliant (GCP and CFR 11).

Highlights

Consistent

Delivering advanced clinical endpoints while reducing variability by automating traceability and consistent reproducibility into every dataset, all underpinned by a highly granular audit trail.

Compatible

Reduces data upload, management and analysis burden for sites, sponsors and readers through seamless integration with existing workflows without the need for additional software or tools.

Flexible

Capabilities in all clinical trial phases, including patient stratification and exploratory endpoints, as well as use for post-market assessment and clinical diagnostics.

Bespoke

Distinct technologies and scientific expertise to meet specific neurological disease needs with the required specialism and complex understanding of each different indication.